BI-1622

• Description :

  BI-1622 is an orally active, potent and highly selective HER2 (ERBB2) inhibitor, with an IC50 of 7 nM. BI-1622 shows greater than 25-fold selectivity over EGFR. BI-1622 shows high antitumor efficacy in vivo in xenograft mouse tumor models with engineered H2170 and PC9 cells and had a favorable agent metabolism and pharmacokinetics profile[1].

• UNSPSC :

  12352005

• Target :

  Btk; CDK; EGFR; Itk; JAK; PI4K; Raf

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/bi-1622.html

• Purity :

  98.97

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(N1CCN(CC1)C2=NC3=C(NC4=CC=C(C(C)=C4)OC5=CC6=NC=NN6C=C5)N=CN=C3C=N2)C=C

• Molecular Formula :

  C26H24N10O2

• Molecular Weight :

  508.53

• References & Citations :

  [1]Lamarre L, et al. Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling. Nat Cancer. 2022 Jul;3 (7) :821-836.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK11; EGFR/ErbB1/HER1; ErbB2/HER2; ErbB4/HER4; JAK3

• CAS Number :

  [2681392-19-6]